Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alogliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alogliptin SCHEMBL121028 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL17036596 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL174188 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL475872 | 0.99 | DPP4 (0.98) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL17781892 | 0.99 | DPP4 (0.98) | DPP4OPRM1OPRK1DPP8 | |
| SCHEMBL23712233 | 0.97 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| SCHEMBL391800 | 0.97 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| SCHEMBL28406504 | 0.95 | DPP4 (0.91) | DPP4OPRM1OPRK1 | |
| Alogliptin SCHEMBL1071798 | 0.94 | DPP4 (0.91) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL476232 | 0.93 | DPP4 (0.86) | DPP4OPRM1OPRK1DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3436 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636284-B2 | Compositions for use in the prevention and/or treatment of intellectual disability and neurodegenerative diseases in a subject with down syndrome | Universita' Degli Studi Di Roma “La Sapienza” (IT) | 2026-05-26 | — | — | US | claimed |
| EP-4735023-A2 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | Piton Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4734978-A2 | COMBINATION THERAPIES USING PSILOCYBIN | University of Padova (IT) | 2026-05-06 | — | — | EP | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-12599564-B2 | Antidiabetic pharmaceutical compositions | Elite Pharmaceutical Solution Inc. (US) | 2026-04-14 | — | — | US | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| US-12582607-B2 | Implantable medical devices for extended release of therapeutic agents | NANO PRECISION MEDICAL, INC. (US) | 2026-03-24 | — | — | US | claimed |
| EP-4705280-A1 | DIARYL UREA-BASED COMPOUNDS AND RELATED COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DIABETES MELLITUS AND NEURODEGENERATIVE DISEASE | Purdue Research Foundation (US) | 2026-03-11 | — | — | EP | claimed |
| US-20220079895-A1 | COMPOSITION FOR PREVENTING OR TREATING LIVER DISEASES | ACEBIOMED, INC. (KR) | 2022-03-17 | — | — | US | claimed |
| EP-3967302-A1 | COMPOSITION FOR PREVENTING OR TREATING LIVER DISEASES | Acebiomed, Inc. (KR) | 2022-03-16 | — | — | EP | claimed |
| WO-2022051319-A1 | FIXED DOSE COMBINATIONS OF CHS-131 AND A DPP-4 INHIBITOR | Coherus Biosciences, Inc. (US) | 2022-03-10 | — | — | WO | claimed |
| EP-3411026-B1 | USE OF STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | CYCLERION THERAPEUTICS INC (US) | 2022-03-09 | — | — | EP | claimed |
| US-20220064146-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | claimed |
| US-20220062379-A1 | METHODS AND COMPOSITIONS FOR MODULATING IMMUNE DYSREGULATION | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2022-03-03 | — | — | US | claimed |
| US-20220054406-A1 | COMPOSITION AND METHOD FOR TREATMENT OF DIABETES | BIOKIER, INC. (US) | 2022-02-24 | — | — | US | claimed |
| EP-3955913-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | ENZYCHEM LIFESCIENCES (KR) | 2022-02-23 | — | — | EP | claimed |
| CN-114057685-A | Preparation method of alogliptin benzoate with high yield | 西安新通药物研究有限公司 | 2022-02-18 | — | — | CN | claimed |
| EP-3946343-A1 | LOW-DOSE TRIPLE COMBINATION FORMULATION | The George Institute For Global Health (AU) | 2022-02-09 | — | — | EP | claimed |